An independent panel convened this week by the National Institutes of Health has concluded that many men with localized, low-risk prostate cancer should be closely monitored, permitting treatment to be delayed until warranted by disease progression.

Related posts:

  1. Medicare: Independent panel to present findings on role of active surveillance in the management of localized prostate cancer Prostate cancer is the second leading cause of cancer-related deaths among men in the United States. It is estimated that in 2010, approximately 32,000 American men died of prostate cancer and 218,000 were newly diagnosed with the disease....
  2. Funded study shows reduction in death for men with intermediate-grade prostate cancer Short-term hormone therapy given in combination with radiation therapy to men with early-stage prostate cancer increased their chances of living longer compared to treatment with radiation therapy alone, according to a clinical trial supported by the National Cancer Institute (NCI), part of the National Institutes of Health. Benefits of the combined treatment were limited mainly […]...
  3. Funded study shows increased prostate cancer risk from vitamin E supplements Men who took 400 international units (I.U.) of vitamin E daily had more prostate cancers compared to men who took a placebo, according to an updated review of data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT)....
  4. Medicare, Aiming for Near-Normal, Blood Sugar Did Not Delay Combined Risk of Diabetic Damage for People With Long-standing Diabetes, NIH-Sponsored Trial Finds In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was […]...
  5. People with a form of muscular dystrophy may have elevated cancer risk Adults with a form of muscular dystrophy called myotonic muscular dystrophy (MMD) may be at increased risk of developing cancer, according to a study by investigators at the National Cancer Institute (NCI), part of the National Institutes of Health....
  6. Medicare Health Checkups – Comparing Models that Assess Breast Cancer Risk A new study found that models for assessing breast cancer risk perform only slightly better when they include common inherited genetic variants recently linked to the disease. For now, recommendations for breast cancer screening or treatments that are based on such models will remain unchanged for most women....
  7. Medicare, Independent panel discourages routine use of treatment regimen for premature infants Premature infants often suffer from respiratory problems due to their underdeveloped lungs. Over the past decade, many of these infants have been treated with inhaled nitric oxide — a treatment designed to ease breathing by widening blood vessels in the lungs. This week, an independent panel convened by the National Institutes of Health determined that […]...
  8. Medicare – Targeting the Blood-Brain Barrier, May Delay Progression of Alzheimer’s Disease Researchers may be one step closer to slowing the onset and progression of Alzheimer's disease. An animal study supported by the National Institute of Environmental Health Sciences (NIEHS), ...
  9. Researchers design a light therapy that targets and destroys cancer cells in mice Researchers have designed a light-based therapy that allows the selective destruction of tumor cells in mice without harming surrounding normal tissue. This method of cancer therapy could theoretically work against tumors in humans, such as those of the breast, lung, prostate, as well as cancer cells in the blood such as leukemias, say scientists from […]...
  10. Medicare: Study finds broad spectrum of cancer risk for organ transplant recipients in US Organ transplant recipients in the United States have a high risk of developing 32 different types of cancer, according to a new study of transplant recipients which fully describes the range of malignancies that occur....
  11. Women exposed to DES in the womb face increased cancer risk A large study of the daughters of women who had been given DES, the first synthetic form of estrogen, during pregnancy has found that exposure to the drug while in the womb (in utero) is associated with many reproductive problems and an increased risk of certain cancers and pre-cancerous conditions. The results of this analysis, […]...
  12. Medicare Card, Scientists Identify Markers, Human Breast Cancer Cells, Linked to Development of an Aggressive, But Less Common Form of Breast Cancer Scientists have identified a group of surface markers on cells linked to an aggressive type of breast cancer called estrogen receptor-negative cancer. In this preliminary study, estrogen-negative breast cancer developed when three markers, CD44+, CD49fhi, and CD133hi were present simultaneously on the surface of human cells taken from breast cancer patients and transplanted into a […]...
  13. Panel Calls for Reducing Colorectal Cancer Deaths by Striking Down Barriers to Screening Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Despite evidence and guidelines supporting the value of screening for this disease, rates of screening for colorectal cancer are consistently lower than those for other types of cancer, particularly breast and cervical. ...
  14. Clinical trial stopped on combination cholesterol treatment The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular […]...
  15. Medicare, Medicare Card, Statement by HHS, NIH Director Regarding the President’s Intent, Appoint Dr. Harold Varmus as Director of the National Institute of Cancer at the National Institutes of Health Dr. Harold Varmus brings a vast wealth of expertise to this key leadership position at the Department. Among his many professional distinctions, he is a Nobel laureate in cancer genetics; has been president of one of the premier cancer research and treatment institutions for the past decade; and previously has served the public as NIH […]...